Related references
Note: Only part of the references are listed.The Role of Ablative Radiotherapy in Older Adults With Limited Metastatic Disease
Bill H. H. Diplas et al.
SEMINARS IN RADIATION ONCOLOGY (2022)
Oligometastases: history of a hypothesis
Michael T. Milano et al.
ANNALS OF PALLIATIVE MEDICINE (2021)
Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression ― Interim Analysis of the First Randomized Study of Stereotactic Body Radiotherapy in Patients With Oligoprogressive Metastatic Cancers of the Lung and Breast
C.J. Tsai et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Technical Giants But Biologic Infants: Defining a More Sophisticated Role for Local Therapy in Metastatic Disease
Sophia C. Kamran et al.
SEMINARS IN RADIATION ONCOLOGY (2021)
Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review
Diego Cortinovis et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial
Chad Tang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
Matthias Guckenberger et al.
LANCET ONCOLOGY (2020)
Consolidative Radiotherapy in Oligometastatic Lung Cancer: Patient Selection With a Prediction Nomogram
Cole Friedes et al.
CLINICAL LUNG CANCER (2020)
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Shirish Gadgeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Beyond Oligometastases
David A. Palma et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A. Palma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Stereotactic reirradiation for local failure of brain metastases following previous radiosurgery: Systematic review and meta-analysis
Mauro Loi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
Yolande Lievens et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Initial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer
Philip Sutera et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma
Ciro Franzese et al.
JOURNAL OF UROLOGY (2019)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al.
LANCET RESPIRATORY MEDICINE (2019)
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
Daniel R. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma et al.
LANCET (2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
Integrated molecular and clinical staging defines the spectrum of metastatic cancer
Sean P. Pitroda et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases
Rosario Mazzola et al.
FRONTIERS IN ONCOLOGY (2019)
Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer
Masayuki Shirasawa et al.
PLOS ONE (2019)
Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial
Joshua M. Bauml et al.
JAMA ONCOLOGY (2019)
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
David A. Palma et al.
BMC CANCER (2019)
Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy
Aman Sharma et al.
ACTA ONCOLOGICA (2019)
The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases
N. Andratschke et al.
BMC CANCER (2018)
Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer
Alexander L. Chin et al.
CLINICAL LUNG CANCER (2018)
Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer
W. Jeffrey Petty et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression
Catherine A. Pembroke et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Prognostic value of combining a quantitative image feature from positron emission tomography with clinical factors in oligometastatic non-small cell lung cancer
Garrett L. Jensen et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer
John Conibear et al.
BMJ OPEN (2018)
Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis
Shangbiao Li et al.
JOURNAL OF THORACIC DISEASE (2018)
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer A Phase 2 Randomized Clinical Trial
Puneeth Iyengar et al.
JAMA ONCOLOGY (2018)
Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450)
Dirk De Ruysscher et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study
Rosario Mazzola et al.
MEDICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R. Weichselbaum et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Patterns of Distant Metastases After Surgical Management of Non-Small-cell Lung Cancer
Jordan A. Torok et al.
CLINICAL LUNG CANCER (2017)
Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer
Jochen Fleckenstein et al.
BMC CANCER (2016)
Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases A Randomized Clinical Trial
Paul D. Brown et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Peter Goldstraw et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
Daniel R. Gomez et al.
LANCET ONCOLOGY (2016)
Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group stereotactic radiotherapy
Juliane Rieber et al.
LUNG CANCER (2016)
Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases
Mette Marie Fode et al.
RADIOTHERAPY AND ONCOLOGY (2015)
14q32-encoded microRNAs mediate an oligometastatic phenotype
Abhineet Uppal et al.
ONCOTARGET (2015)
Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients
C. Collen et al.
ANNALS OF ONCOLOGY (2014)
An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non-Small-Cell Lung Cancer
Allison B. Ashworth et al.
CLINICAL LUNG CANCER (2014)
Propensity Scoree-Matched Analysis of Comprehensive Local Therapy for Oligometastatic Non-Small Cell Lung Cancer That Did Not Progress After Front-Line Chemotherapy
Tommy Sheu et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Definitive Primary Therapy in Patients Presenting With Oligometastatic Non-Small Cell Lung Cancer
Ravi B. Parikh et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer
Puneeth Iyengar et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The oligometastatic state-separating truth from wishful thinking
David A. Palma et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Radiation-Induced Equilibrium Is a Balance between Tumor Cell Proliferation and T Cell-Mediated Killing
Hua Liang et al.
JOURNAL OF IMMUNOLOGY (2013)
Radical Treatment of Non-Small-Cell Lung Cancer Patients with Synchronous Oligometastases Long-Term Results of a Prospective Phase II Trial (Nct01282450)
Dirk De Ruysscher et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
Martin Kocher et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
MicroRNA Expression Characterizes Oligometastasis(es)
Yves A. Lussier et al.
PLOS ONE (2011)
Oligometastases and Oligo-recurrence: The New Era of Cancer Therapy
Yuzuru Niibe et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis
Kyle E. Rusthoven et al.
ACTA ONCOLOGICA (2009)
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial
Eric L. Chang et al.
LANCET ONCOLOGY (2009)
An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease
Joseph K. Salama et al.
CLINICAL CANCER RESEARCH (2008)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases - A randomized controlled trial
Hidefumi Aoyama et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
